NeuroPace, Inc. announced the appointment of Michael Favet as Chief Executive Officer, Frank Fischer, after 20 years serving as CEO, continues with NeuroPace as Chairman of the Board of Directors. Mr. Favet has served on the NeuroPace board since 2016, and has been the acting Chief Commercial Officer since 2018. Mr. Favet has twenty years of experience in senior management positions at a variety of medical technology companies, including Advanced Cardiac Therapeutics, Sonitus Medical, Ventus Medical, Boston Scientific and Guidant.

Most recently, Mr. Favet was a managing director for KCK's medtech group, part of a family fund investing in medical technologies. For more than 20 years, Mr. Fischer has worked to ensure that NeuroPace has met the highest possible standards on behalf of patients and health care providers, from initial conception through successful product commercialization. As Chairman of the Board, he will continue work with the leadership team and external partners to continue advancing RNS therapy and improving access to care for individuals living with uncontrolled epilepsy.